UNSPSC 51111700: Antineoplastic antibiotics

This classification denotes antibiotics that inhibit or prevent the proliferation of neoplasms, or proliferation of new abnormal growths of tissue, and which are therefore called ANTI-NEOPLASTICS, ANTINEOPLASTICS, or ANTINEOPLASTIC ANTIBIOTICS.

UNSPSC 51111700 Antineoplastic antibiotics is a Class code covering pharmaceutical products used in cancer treatment that state and local health agencies and pharmacy benefit programs procure through both traditional and emerging direct-contracting channels. Recent state and local procurement activity under this code centers on acquisition models and vendor capabilities rather than spot purchases of specific drug formulations — health systems and state pharmacy programs are actively evaluating how to source these high-cost oncology drugs through direct manufacturer relationships, value-based pricing arrangements, and alternative distribution channels outside traditional pharmacy benefit manager and group purchasing organization intermediaries. The issuing bodies pursuing these opportunities span state health and human services departments managing Medicaid and employee health plans, with Texas Health and Human Services Commission representing the most visible recent buyer.

Texas Health and Human Services Commission issued Request for Information (RFI) HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs that would establish relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve fulfillment efficiency and cost management. The RFI solicits information from vendors about direct contracting experience with self-insured employers and government health plans, negotiated net pricing models without rebates, and outcomes-based or value-based agreement capacity. This is exploratory market research; no award value, budget range, or formal response deadline with binding commitment is specified, as the state intends to use vendor responses to develop detailed specifications and pricing models for subsequent formal solicitations.